moxifloxacin has been researched along with Stevens-Johnson Syndrome in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, A; Das, A; Tripathy, K | 1 |
| Kim, J; Midgley, KJ; Ullman, MA; Ullman, S | 1 |
| Cartmell, B; Howard-Thompson, A; Suda, KJ | 1 |
| Gregory, DG | 1 |
| Koopmans, RP; Prins, JM | 1 |
| Huddleston, HM; Kingsley, MM; Weaver, CH; Wolverton, SE | 1 |
| Bansal, S; Sachdev, R; Sharma, N; Sinha, R; Titiyal, JS | 1 |
| Brashear, R; Nebesio, C; Nori, S; Travers, JB | 1 |
9 other study(ies) available for moxifloxacin and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Topical moxifloxacin-induced Stevens-Johnson syndrome.
Topics: Anaphylaxis; Humans; Moxifloxacin; Stevens-Johnson Syndrome | 2017 |
Reply: Topical moxifloxacin-induced Stevens-Johnson syndrome.
Topics: Anaphylaxis; Humans; Moxifloxacin; Stevens-Johnson Syndrome | 2017 |
Toxic epidermal necrolysis reaction associated with the use of moxifloxacin.
Topics: Anti-Bacterial Agents; Female; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Stevens-Johnson Syndrome | 2014 |
New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syndrome.
Topics: Acute Disease; Amnion; Anti-Bacterial Agents; Combined Modality Therapy; Cyclosporine; Dexamethasone; Dry Eye Syndromes; Eyelid Diseases; Female; Fluorophotometry; Fluoroquinolones; Glucocorticoids; Guidelines as Topic; Humans; Middle Aged; Moxifloxacin; Prospective Studies; Severity of Illness Index; Stevens-Johnson Syndrome; Tobramycin; Visual Acuity | 2016 |
[Novel side effects of moxifloxacin: making a balanced decision again].
Topics: Adverse Drug Reaction Reporting Systems; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Hepatitis; Humans; Moxifloxacin; Pneumonia; Quinolines; Risk Assessment; Stevens-Johnson Syndrome; Treatment Outcome | 2008 |
Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bronchitis; Chemical and Drug Induced Liver Injury; Europe; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Safety-Based Drug Withdrawals; Sinusitis; Stevens-Johnson Syndrome | 2009 |
Moxifloxacin-induced drug hypersensitivity syndrome with features of toxic epidermal necrolysis.
Topics: Adult; Anti-Infective Agents; Asian People; Aza Compounds; Drug Hypersensitivity; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Stevens-Johnson Syndrome | 2009 |
Bilateral microbial keratitis in highly active antiretroviral therapy-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a case series.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amnion; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Aza Compounds; Benzamidines; Carboxymethylcellulose Sodium; Cefazolin; Chlorhexidine; Corneal Ulcer; Drug Therapy, Combination; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pain; Quinolines; Stevens-Johnson Syndrome; Tobramycin; Treatment Outcome; Tropanes; Visual Acuity | 2011 |
Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Drug Hypersensitivity; Fatal Outcome; Female; Fluoroquinolones; Humans; Liver Failure, Acute; Moxifloxacin; Quinolines; Respiratory Tract Diseases; Stevens-Johnson Syndrome | 2004 |